Cargando…

Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C

Promoter methylation-associated silencing of cancer-associated microRNAs (miRNAs) is a common epigenetic mechanism during tumorigenesis in various types of human cancer. However, this has not been comprehensively examined in endometrial carcinoma (EC). In the present study, an miRNA microarray consi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jianjiao, Liang, Shanhui, Shan, Boer, Tian, Wenjuan, Wang, Huaying, Ren, Yulan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169941/
https://www.ncbi.nlm.nih.gov/pubmed/32186750
http://dx.doi.org/10.3892/ijmm.2020.4540
_version_ 1783523822875443200
author Ni, Jianjiao
Liang, Shanhui
Shan, Boer
Tian, Wenjuan
Wang, Huaying
Ren, Yulan
author_facet Ni, Jianjiao
Liang, Shanhui
Shan, Boer
Tian, Wenjuan
Wang, Huaying
Ren, Yulan
author_sort Ni, Jianjiao
collection PubMed
description Promoter methylation-associated silencing of cancer-associated microRNAs (miRNAs) is a common epigenetic mechanism during tumorigenesis in various types of human cancer. However, this has not been comprehensively examined in endometrial carcinoma (EC). In the present study, an miRNA microarray consisting of 1,347 common human miRNAs was used to select potential tumor suppressive miRNAs that were hyper-methylated in EC. This led to the identification of miR-638, miR-210 and miR-3665. The methylation status of miR-638 was examined by bisulfite sequencing polymerase chain reaction and miR-638 expression was measured by TaqMan miRNA assays. EC cell lines transfected with vectors overexpressing miR-638, its target gene myocyte enhancer factor 2C (MEF2C) or both, were constructed. Dual-luciferase reporter assays, a xenograft mouse model and rescue experiments were designed to study miR-638 and its target gene MEF2C. The results indicated that the promoter region of miR-638 was highly methylated and the expression of miR-638 was significantly downregulated in cancerous tissues from 42 patients with EC who underwent surgical resection. Additionally, a low expression of miR-638 was significantly associated with advanced Federation of Gynecology and Obstetrics stage and was demonstrated to indicate shorter disease-free survival. Functional studies indicated that the overexpression of miR-638 in EC cell lines inhibited in vitro tumor progression and in vivo tumorigenicity. MEF2C was verified as a direct target of miR-638 and was demonstrated to mediate the tumor-suppressive function of miR-638 in EC.
format Online
Article
Text
id pubmed-7169941
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-71699412020-04-24 Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C Ni, Jianjiao Liang, Shanhui Shan, Boer Tian, Wenjuan Wang, Huaying Ren, Yulan Int J Mol Med Articles Promoter methylation-associated silencing of cancer-associated microRNAs (miRNAs) is a common epigenetic mechanism during tumorigenesis in various types of human cancer. However, this has not been comprehensively examined in endometrial carcinoma (EC). In the present study, an miRNA microarray consisting of 1,347 common human miRNAs was used to select potential tumor suppressive miRNAs that were hyper-methylated in EC. This led to the identification of miR-638, miR-210 and miR-3665. The methylation status of miR-638 was examined by bisulfite sequencing polymerase chain reaction and miR-638 expression was measured by TaqMan miRNA assays. EC cell lines transfected with vectors overexpressing miR-638, its target gene myocyte enhancer factor 2C (MEF2C) or both, were constructed. Dual-luciferase reporter assays, a xenograft mouse model and rescue experiments were designed to study miR-638 and its target gene MEF2C. The results indicated that the promoter region of miR-638 was highly methylated and the expression of miR-638 was significantly downregulated in cancerous tissues from 42 patients with EC who underwent surgical resection. Additionally, a low expression of miR-638 was significantly associated with advanced Federation of Gynecology and Obstetrics stage and was demonstrated to indicate shorter disease-free survival. Functional studies indicated that the overexpression of miR-638 in EC cell lines inhibited in vitro tumor progression and in vivo tumorigenicity. MEF2C was verified as a direct target of miR-638 and was demonstrated to mediate the tumor-suppressive function of miR-638 in EC. D.A. Spandidos 2020-06 2020-03-16 /pmc/articles/PMC7169941/ /pubmed/32186750 http://dx.doi.org/10.3892/ijmm.2020.4540 Text en Copyright: © Ni et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Ni, Jianjiao
Liang, Shanhui
Shan, Boer
Tian, Wenjuan
Wang, Huaying
Ren, Yulan
Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title_full Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title_fullStr Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title_full_unstemmed Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title_short Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C
title_sort methylation-associated silencing of mir-638 promotes endometrial carcinoma progression by targeting mef2c
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169941/
https://www.ncbi.nlm.nih.gov/pubmed/32186750
http://dx.doi.org/10.3892/ijmm.2020.4540
work_keys_str_mv AT nijianjiao methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c
AT liangshanhui methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c
AT shanboer methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c
AT tianwenjuan methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c
AT wanghuaying methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c
AT renyulan methylationassociatedsilencingofmir638promotesendometrialcarcinomaprogressionbytargetingmef2c